Orelabrutinib

B-cell Lymphoma

Peking University People's HospitalSmall moleculePhase 3Active

B

63/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 73/ 100

Competitive context

316 Active assets in the B-cell Lymphoma cohort.

Asset / Sponsor	Phase	Rating
VINDESINE Children's Cancer Group, China	Phase 4	BBB
Odronextamab University of Birmingham	Phase 3	BBB
cc-5013 Shanghai Junshi Bioscience Co., Ltd.	Phase 4	BBB
METHOTREXATE Children's Cancer Group, China	Phase 4	BBB
Cytosin-Arabinosid Children's Cancer Group, China	Phase 4	BBB

View all 50 →

Same molecule, other indications

Orelabrutinib is also rated in:

marginal zone lymphomaDormant

BBB

Indicative ·

73 / 100

primary central nervous system lymphomaDormant

BB

Indicative ·

70 / 100

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.